(RTTNews) - Eli Lilly and Company (LLY) said on Wednesday that its investigational EloraTZP combination of eloralintide and tirzepatide delivered substantial weight loss and reductions in blood sugar levels in a Phase 2b trial involving 367 adults with obesity or overweight and type 2 diabetes. After 48 weeks, participants receiving the highest-dose combination of eloralintide 9 mg and tirzepatide 15 mg lost an average of 54.1 pounds, or 23.3 percent of body weight, while A1C declined by 2.9 percent. By comparison, tirzepatide 15 mg alone resulted in an average weight loss of 34.4 pounds, or 14.8 percent, and a 2.4 percent A1C reduction.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.